Sclerostin quo vadis? - is this a useful long-term mortality parameter in prevalent hemodialysis patients?

Abstract

BACKGROUND/AIMS Cardiovascular calcification contributes to the increased mortality in hemodialysis patients. Sclerostin was identified as an antianabolic bone factor causing soft tissue calcification. Data on prospective large-scale studies associating sclerostin with mortality in hemodialysis patients are so far inconsistent. METHODS In our multicenter… (More)
DOI: 10.1159/000368502

6 Figures and Tables

Topics

  • Presentations referencing similar topics